BCAT1 activates the mTORC1 pathway to play a pro-oncogenic role in breast and endometrial cancers, while BCAT1 inhibits mitochondrial reactive oxygen species (ROS) production in breast cancer cells (25, 27, 32). This evidence concerns the gene BCAT1 and endometrial cancer.